Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Akero Therapeutics Inc

Healthcare US AKRO

NoneUSD
0.00(0%)

Last update at 2026-01-08T21:03:16.794274Z

Day Range

--
LowHigh

52 Week Range

15.3237.00
LowHigh

Fundamentals

  • Previous Close 54.65
  • Market Cap2172.15M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-269.26598M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -112.03300M -100.77700M -79.20700M -43.75500M -81.71400M
Minority interest - - - - 0.00000M
Net income -108.91000M -100.73600M -79.19000M -43.75500M -81.71400M
Selling general administrative 29.87M 19.13M 15.24M 8.61M 1.90M
Selling and marketing expenses - - - - -
Gross profit 115.16M -100.88600M -80.15400M - 0.00000M
Reconciled depreciation 0.04M 0.04M 0.02M - -
Ebit -115.15600M -100.92700M -80.17100M -43.75500M -13.77800M
Ebitda -111.29400M -100.88600M -80.15400M -45.65100M -81.71400M
Depreciation and amortization 3.86M 0.04M 0.02M - -67.93600M
Non operating income net other 3.93M 0.09M 0.95M - -
Operating income -115.15600M -100.88600M -80.15400M -45.65100M -13.77800M
Other operating expenses 115.16M 100.89M 80.15M 45.65M 13.78M
Interest expense 0.74M 0.04M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - 62.15M
Net interest income -0.73900M - - - -
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -3.12300M -0.04100M -0.01700M -1.89600M 0.00000M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 115.16M 100.89M 80.15M 45.65M 13.78M
Cost of revenue -115.15600M 100.89M 80.15M - 0.00000M
Total other income expense net 3.12M 0.11M 0.95M 1.90M -67.93600M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -111.96900M -100.80100M -79.20700M -43.75500M -81.71400M
Net income applicable to common shares -112.03300M -100.77700M -79.20700M -43.75500M -82.23400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 580.27M 356.57M 195.55M 273.34M 138.12M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 9.95M 3.72M 5.32M 2.96M 1.65M
Total liab 44.97M 30.01M 26.44M 14.63M 9.39M
Total stockholder equity 535.31M 326.56M 169.11M 258.71M 128.73M
Deferred long term liab - 0.30M - 0.05M -
Other current liab 11.83M 10.79M 18.22M 9.39M 8.42M
Common stock 0.00600M 0.00500M 0.00400M 0.00400M 0.00300M
Capital stock 0.00600M 0.00500M 0.00400M 0.00400M 0.00300M
Retained earnings -574.09600M -422.33700M -310.30400M -209.52700M -130.32000M
Other liab - 0.30M - - 0.02M
Good will - - - - -
Other assets 0.00000M 0.11M 0.42M 0.20M 0.07M
Cash 234.21M 249.77M 150.48M 187.24M 136.40M
Cash and equivalents - - - - -
Total current liabilities 19.13M 19.08M 25.13M 13.11M 9.37M
Current deferred revenue - - - - -
Net debt -208.16400M -238.82800M -148.96700M -185.43200M -136.40000M
Short term debt 0.26M 0.33M 0.20M 0.29M -
Short long term debt - - - - -
Short long term debt total 26.04M 10.95M 1.52M 1.81M -
Other stockholder equity 1109.13M 748.86M 479.44M 468.24M 120.93M
Property plant equipment - 0.05M 0.09M 1.79M -
Total current assets 559.96M 355.17M 193.58M 271.35M 138.05M
Long term investments 19.28M - - - -
Net tangible assets - 326.56M 169.11M 258.71M 128.73M
Short term investments 315.80M 101.68M 37.77M 81.14M 71.61M
Net receivables - - 0.42M 0.20M -
Long term debt 24.96M 9.54M - - -
Inventory - - - - -
Accounts payable 7.04M 7.97M 6.71M 3.43M 0.95M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.27M 0.04M -0.02700M -0.00300M -0.00600M
Additional paid in capital - - - - -
Common stock total equity - 0.00500M 0.00400M 0.00400M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - -422.33700M -310.30400M -209.52700M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M 0.11M 0.42M 0.20M 0.07M
Deferred long term asset charges - - - - -
Non current assets total 20.31M 1.40M 1.97M 1.99M 0.07M
Capital lease obligations 1.34M 1.40M 1.52M 1.81M -
Long term debt total - 9.54M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -63.82500M 42.28M -9.76100M -71.51300M -71.51300M
Change to liabilities -6.36500M 12.01M 2.48M -0.42600M 1.31M
Total cashflows from investing activities -63.82500M 42.28M -9.76100M -71.51300M -5.00000M
Net borrowings 9.61M 10.00M 10.00M 10.00M 0.00000M
Total cash from financing activities 255.63M 0.60M 203.11M 95.99M 85.01M
Change to operating activities -5.42700M 6.45M -0.39600M 6.89M -0.25200M
Net income -112.03300M -100.77700M -79.20700M -43.75500M -81.71400M
Change in cash 99.29M -36.79900M 122.54M -11.15200M 75.38M
Begin period cash flow 150.59M 187.39M 64.85M 76.00M 0.62M
End period cash flow 249.88M 150.59M 187.39M 64.85M 76.00M
Total cash from operating activities -92.51700M -79.68100M -70.80400M -35.62700M -4.62500M
Issuance of capital stock 241.20M 0.00000M 202.55M 95.45M 85.50M
Depreciation 0.04M 0.04M 0.02M -0.10400M 0.02M
Other cashflows from investing activities - - - -71.51300M -5.00000M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables - - - - 0.00000M
Sale purchase of stock 0.28M 0.37M 0.20M 0.09M 85.51M
Other cashflows from financing activities 14.55M 0.23M 0.35M 0.45M 85.01M
Change to netincome 23.52M 10.06M 6.30M 1.67M 76.03M
Capital expenditures 0.00000M 0.00000M 0.15M 0.15M 5.00M
Change receivables - - - - -
Cash flows other operating 2.12M -2.08000M -1.32000M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 99.29M -36.79900M 122.54M - -
Change in working capital -4.45900M 9.73M 2.08M 6.46M 1.06M
Stock based compensation 23.24M 10.05M 6.02M 1.77M 0.12M
Other non cash items 0.69M 0.20M 0.20M -0.10400M 75.91M
Free cash flow -92.51700M -79.68100M -70.95200M -35.62700M -9.62500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
AKRO
Akero Therapeutics Inc		 - -% - - - - 2.94 -6.7701
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Akero Therapeutics Inc

601 Gateway Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Andrew Cheng M.D., Ph.D. Pres, CEO & Director 1967
Dr. Jonathan M. Young J.D., Ph.D. Co-Founder, Exec. VP, COO & Sec. 1970
Dr. Timothy Rolph Co-Founder & Chief Scientific Officer 1954
Mr. William R. White J.D. Exec. VP, CFO, Treasurer & Head of Corp. Devel. 1973
Ms. Catriona Yale Exec. VP & Chief Devel. Officer 1972
Mr. John J. Schembri VP of Fin. & Controller 1962
Dr. Andrew Cheng M.D., Ph.D. President, CEO & Director 1967
Dr. Jonathan M. Young J.D., Ph.D. Co-Founder, Executive VP, COO & Secretary 1970
Mr. William R. White J.D. Executive VP, CFO, Treasurer & Head of Corporate Development 1974
Ms. Catriona Yale Executive VP & Chief Development Officer 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.